Boston Scientific Co. (NYSE:BSX) SVP Maulik Nanavaty sold 3,038 shares of the company’s stock in a transaction that occurred on Tuesday, January 15th. The shares were sold at an average price of $35.46, for a total value of $107,727.48. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Maulik Nanavaty also recently made the following trade(s):

  • On Friday, November 16th, Maulik Nanavaty sold 23,458 shares of Boston Scientific stock. The shares were sold at an average price of $37.28, for a total value of $874,514.24.

Shares of BSX opened at $37.69 on Friday. Boston Scientific Co. has a 12-month low of $25.04 and a 12-month high of $39.44. The company has a current ratio of 0.78, a quick ratio of 0.56 and a debt-to-equity ratio of 0.58. The firm has a market capitalization of $50.94 billion, a P/E ratio of 29.91, a PEG ratio of 2.14 and a beta of 0.72.

Boston Scientific (NYSE:BSX) last issued its earnings results on Wednesday, October 24th. The medical equipment provider reported $0.35 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.34 by $0.01. Boston Scientific had a return on equity of 26.44% and a net margin of 6.93%. The company had revenue of $2.39 billion for the quarter, compared to analysts’ expectations of $2.40 billion. During the same period last year, the business earned $0.31 EPS. Boston Scientific’s quarterly revenue was up 7.7% compared to the same quarter last year. As a group, sell-side analysts forecast that Boston Scientific Co. will post 1.39 earnings per share for the current fiscal year.

A number of equities analysts have issued reports on the company. Argus increased their price target on Boston Scientific from $41.00 to $43.00 and gave the stock a “buy” rating in a report on Friday, October 26th. Guggenheim increased their price target on Boston Scientific to $45.00 and gave the stock a “buy” rating in a report on Friday, November 16th. Zacks Investment Research cut Boston Scientific from a “hold” rating to a “sell” rating in a report on Monday, December 31st. Needham & Company LLC restated a “buy” rating and set a $43.00 price target on shares of Boston Scientific in a report on Tuesday, January 8th. Finally, Barclays assumed coverage on Boston Scientific in a report on Monday, October 15th. They set an “overweight” rating and a $43.00 price target on the stock. Three equities research analysts have rated the stock with a hold rating, twenty-two have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $40.12.

Institutional investors and hedge funds have recently modified their holdings of the stock. Ipswich Investment Management Co. Inc. purchased a new stake in Boston Scientific in the 4th quarter valued at $28,000. West Oak Capital LLC raised its position in Boston Scientific by 40.0% in the 4th quarter. West Oak Capital LLC now owns 1,050 shares of the medical equipment provider’s stock valued at $37,000 after buying an additional 300 shares during the last quarter. North Star Investment Management Corp. raised its position in Boston Scientific by 111.1% in the 4th quarter. North Star Investment Management Corp. now owns 2,280 shares of the medical equipment provider’s stock valued at $81,000 after buying an additional 1,200 shares during the last quarter. Moody National Bank Trust Division purchased a new stake in Boston Scientific in the 3rd quarter valued at $108,000. Finally, Capital Guardian Trust Co. purchased a new stake in Boston Scientific in the 3rd quarter valued at $110,000. Institutional investors own 90.71% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Insider Selling: Boston Scientific Co. (BSX) SVP Sells $107,727.48 in Stock” was first published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are viewing this piece on another publication, it was stolen and reposted in violation of U.S. and international copyright and trademark laws. The original version of this piece can be viewed at https://theolympiareport.com/2019/01/19/insider-selling-boston-scientific-co-bsx-svp-sells-107727-48-in-stock.html.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: Cardiovascular, Rhythm Management, and MedSurg. The company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions therapy products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as certain peripheral vessels; and structural heart therapy systems.

See Also: Balanced Fund

Insider Buying and Selling by Quarter for Boston Scientific (NYSE:BSX)

Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.